Sitemap
- The Penn Vasculitis Center: A Leader in Vasculitis
- Meet the Team
- Research
- Patient Care
- Donate
- A Randomized Multicenter Study for Isolated Skin Vasculitis (ARAMIS)
- Study of Investigational Drug NS-229 to Treat EGPA
- Depemokimab Compared with Mepolizumab for Patients with EGPA on Standard of Care Therapy (OCEAN)
- Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
- Abatacept in Giant Cell Arteritis (ABAGART)
- Nasal Microbiome in ANCA Associated Vasculitis and Relapsing Polychondritis (NMB)
- Redefining Autoimmune Diseases Across Rheumatology (RADAR)
- VCRC Genetic Repository One-Time DNA Study
- VCRC Longitudinal Study of Central Nervous System Vasculitis (CNSV)
- VCRC Longitudinal Study of EGPA
- VCRC Longitudinal Study of Relapsing Polychondritis (RP)
- Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)
- Vasculitis Sino-Nasal Indicators for Flares (V-SNIFF)
- Study of Immunomodulatory Medications for Patients with RP (PROSPECT)
- Long-term Safety and Efficacy of Avacopan in Participants With ANCA-associated Vasculitis
- ABROGATE (GPA)
- RaVeR (GPA and MPA)
- PEXIVAS (GPA and MPA)
- RITAZAREM (GPA)
- GiACTA (GCA)
- DCVAS (primary systemic vasculitis)
- MEA115921 (EGPA)
- CLASSIC (GPA and MPA)
- Mepolizumab Long-term Access Program (EGPA)
- ADVOCATE (GPA and MPA)
- InflaRx (GPA and MPA)
- TEMPO (GPA)
- Randomized, Double-Blind Trial of Abatacept for the Treatment of Giant Cell Arteritis